Skip to main content
  • Bookmarks
  • Register
  • Login

NIH OIR/OTT Logo

Main Menu

  • Partnerships

    Partnerships

    These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

    • Overview
    • Opportunities
    • Featured Technologies
    • Collaboration / CRADAs
    • Licensing Process
    • Forms / Model Agreements
    • Startups
    • Non-Profits
    • License Materials
    • Licensing FAQs
    • Business Opportunities
    • Product Showcase
    • Product Pipeline
    • Federal Register Notices

    The NIH cannot commercialize its discoveries even with its considerable size and resources — it relies instead upon partners. Typically, a royalty-bearing exclusive license agreement with the right to sublicense is given to a company from NIH to use patents, materials, or other assets to bring a therapeutic or vaccine product concept to market.

  • Royalties

    Royalties

    Information for inventors and licensees on the administration of royalties.

    • Information for NIH Inventors
    • Information for Licensees
    • License Notices / Reports
    • Royalty Coordinators
    • NIH Payment Center
    • CDC Payment Center

    Each year, hundreds of new inventions are made at NIH and CDC laboratories. Nine NIH Institutes or Centers (ICs) transfer NIH and CDC inventions through licenses to the private sector for further research and development and eventual commercialization.

  • Reports

    Reports

    These links provide access to reports tracking the success of NIH licensed products.

    • Annual Reports
    • Tech Transfer Statistics
    • Tech Transfer Metrics
    • Commercial Outcomes
    • HHS License-Based Vaccines & Therapeutics
    • Public Health & Economic Impact Study
    • Stories of Discovery
    • Chen Lecture Videos
    • NIH Patents and Active Patent Commercialization Licenses
    • Media Room
    • Tech Transfer Newsletters
    • NIH Patents and Patent Applications

    The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day. Reports are generated from the commonly tracked metrics related to these products.

  • Resources

    Resources

    These links provide resources to those interested in the technology transfer activities at NIH.

    • Forms and Model Agreements
    • License Notices / Reports
    • Video Library
    • Inventor Resources
    • Presentations & Articles
    • FAQs
    • RSS Feeds
    • Inventor Showcase

    Past videos, lectures, presentations, and articles related to technology transfer at NIH are kept and made available to the public. These topics range from general technology transfer information to processes specific to NIH.

  • Policy & Regulations

    Policies & Regulations

    These links provide access to the policies and regulations surrounding partnering or collaborating with NIH.

    • Freedom of Information Act (FOIA)
    • PHS Technology Transfer Policy
    • Policies & Reports
    • Useful Links

    If a company would like to acquire rights to use or commercialize either an unpatented material, or a patented or patent-pending invention, a license is required. There are numerous policies and regulations surrounding the transfer or a technology from the NIH to a company or organization.

  • About

    About Us

    These links provide information about the Office of Technology Transfer.

    • Contact Us
    • Staff Directory
    • Management
    • FAQs
    • HHS Tech Transfer Offices & Contacts
    • Careers in Tech Transfer
    • Location & Directions
    • Feedback

    The NIH Office of Technology Transfer (OTT) plays a strategic role by supporting the patenting and licensing efforts of our NIH ICs. OTT protects, monitors, markets and manages the wide range of NIH discoveries, inventions, and other intellectual property as mandated by the Federal Technology Transfer Act and related legislation.

Breadcrumb

  1. Home
  2. Taxonomy
  3. Term
  4. NCI

ANALYSIS OF LARGE NUMBERS OF ESTROGENS AND OTHER STEROIDS AND
APPLICATIONS THEREOF

  • Read more about ANALYSIS OF LARGE NUMBERS OF ESTROGENS AND OTHER STEROIDS AND APPLICATIONS THEREOF
US Application 60/688,160
Filed on 2005-06-07

Anti-CD30 Antibodies That Bind to Intact CD30 But Not Soluble CD30

  • Read more about Anti-CD30 Antibodies That Bind to Intact CD30 But Not Soluble CD30
US Application 60/681,929
Filed on 2005-05-16

Induction of C/EBPalpha and Uses Thereof

  • Read more about Induction of C/EBPalpha and Uses Thereof
US Application 60/699,971
Filed on 2005-07-15

Angio-inhibitory Peptides Derived From Human TIMP-2

  • Read more about Angio-inhibitory Peptides Derived From Human TIMP-2
US Application 60/728,146
Filed on 2005-10-18

Scytovirin Domain 1 Related Polypeptides

  • Read more about Scytovirin Domain 1 Related Polypeptides
US Application 60/684,353
Filed on 2005-05-25

A Single Ribozyme To Catalyze Both Trimming And Trans-Acting Catalysis275

  • Read more about A Single Ribozyme To Catalyze Both Trimming And Trans-Acting Catalysis275
US Application 60/675,076
Filed on 2005-04-25

A Phase II Clinical Trail Of Anethole Dithiolethione (Sialor) In Smokers With Bronchial Dysplasia

  • Read more about A Phase II Clinical Trail Of Anethole Dithiolethione (Sialor) In Smokers With Bronchial Dysplasia
US Application 60/355,826
Filed on 2002-02-13

Intraperitoneal Injection of Pseudovirions Carrying a Toxin Leads to Significantly Reduced Tumor Size

  • Read more about Intraperitoneal Injection of Pseudovirions Carrying a Toxin Leads to Significantly Reduced Tumor Size
US Application 60/741,831
Filed on 2005-12-01

Identification Of H2-Db And HLA A2 Specific CD8 Epitopes From VEGFR2/KDR That Inhibit Angiogenesis By Vaccination

  • Read more about Identification Of H2-Db And HLA A2 Specific CD8 Epitopes From VEGFR2/KDR That Inhibit Angiogenesis By Vaccination
US Application 60/671,867
Filed on 2005-04-15

Inhibition Of SMAD-signaling Leads To Enhanced Insulin Production And Better Glucose Control A Potential Therapy For Diabetes And Associated Complications Due To Hyperglycemina

  • Read more about Inhibition Of SMAD-signaling Leads To Enhanced Insulin Production And Better Glucose Control A Potential Therapy For Diabetes And Associated Complications Due To Hyperglycemina
US Application 60/776,555
Filed on 2006-02-23

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 154
  • Page 155
  • Page 156
  • Page 157
  • Page 158
  • Page 159
  • Page 160
  • Page 161
  • Page 162
  • …
  • Next page ››
  • Last page Last »
Subscribe to NCI
NIH White Technology Transfer Logo

Return to Top

  • About
  • Privacy Notice
  • Accessibility
  • Web Policies & Notices
  • Open Data
  •  
  • For NIH Staff Only
  • HHS
  • NIH
  • HHS Vulnerability Disclosure
  • Connect
  • Twitter
  • LinkedIn
  • Contact
  • Feedback

Office of Technology Transfer, Office of Intramural Research, National Institutes of Health